I hereby certify that this correspondence is being deposited with the U.S. Postal Service as Express Mail, Airbill No. EV 301-210-233 US, in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.

Docket No.: CIBT-P02-130

(PATENT)

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:

Huston et al.

Application No.: Not Yet Assigned

Confirmation No.:

Filed: October 10. 2003

Art Unit: N/A

For:

BIOSYNTHETIC BINDING PROTEINS FOR

IMMUNO-TARGETING

Examiner: Not Yet Assigned

### INFORMATION DISCLOSURE STATEMENT (IDS)

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 CFR 1.56, 1.97 and 1.98, the attention of the Patent and Trademark Office is hereby directed to the references listed on the attached PTO/SB/08. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

This Information Disclosure Statement accompanies the new patent application submitted herewith.

Those patent(s) or publications(s) in the attached form Form PTO-1449 are not supplied because they were previously cited by or submitted to the Office in a prior application number 09/558,741, filed April 26, 2000 and relied upon in this application for an earlier filing date under 35 U.S.C.120.

In accordance with 37 CFR 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 CFR 1.56(a) exists. In accordance with 37 CFR 1.97(h), the filing of this

Application No.: Not Yet Assigned Docket No.: CIBT-P02-130

Information Disclosure statement shall not be construed to be an admission that any patent, publication or other information referred to therein is "prior art" for this invention unless specifically designated as such.

It is submitted that the Information Disclosure Statement is in compliance with 37 CFR 1.98 and the Examiner is respectfully requested to consider the listed references.

The Director is hereby authorized to charge any deficiency in the fees filed, asserted to be filed or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Deposit Account No. 18-1945, under Order No. CIBT-P02-130. A duplicate copy of this paper is enclosed.

Dated: October 10, 2003

Respectfully submitted,

Melissa S. Rones, Ph.D.

Registration No.: 54,408

ROPES & GRAY LLP

One International Place

Boston, Massachusetts 02110-2624

(617) 951-7000

(617) 951-7050 (Fax)

Attorneys/Agents For Applicant

EXAM. INIT.  CA Saul  pp. Frag	DATE   09/18   10/30   06/28	U.S. I	erial	NO: Husto No: 09/ DATE: 4/ DOCUMENTE	558,7 26/00	741		GROUE	': un	assig	
INIT.   NUMBER     AA	DATE   09/18   10/30   06/28	U.S. I	LLING I	DATE: 4/	26/00	0			': un		
INIT.   NUMBER     AA	DATE   09/18   10/30   06/28	U.S. I	PATENT NAH	DOCUHEN					': un		
INIT.   NUMBER     AA	DATE   09/18   10/30   06/28	/84   Ga	NAH		TS			CHD			
INIT.   NUMBER     AA	DATE   09/18   10/30   06/28	/84 Ga		E				CITO		TO Y Y YO	
AB 4,479,930  AC 4,753,894  AD 4,946,778  AE 5,091,513  AF 5,132,409  EXAM. DOCUMEN NUMBER  BA W085/035  BB W088/093  BC 0502812  BD W092/156  BE W093/062  EXAM. INIT.  CA Saul  PP. Frage  CB Khay	10/30	T I	ansow		!	CLA	SS	CLAS	SS	•	NG DATE PPROPRIATE
AC 4,753,894  AD 4,946,778  AE 5,091,513  AF 5,132,409  EXAM. DOCUMEN NUMBER  BA W085/035  BB W088/093  BC 0502812  BD W092/156  BE W093/062  EXAM. INIT. CA Saul	06/28	/84 Hr		et al.		436	,   	548			·
AD 4,946,778  AE 5,091,513  AF 5,132,409  EXAM. DOCUMEN NUMBER  BA W085/035  BB W088/093  BC 0502812  BD W092/156  BE W093/062  EXAM. INIT.  CA Saul  Pp. Frag	<del> </del>		natowi	ch		424		1.1		l 1	·
EXAM.   DOCUMEN   NUMBER   BA   W085/035   BB   W088/093   BC   0502812   BD   W092/156   BE   W093/062   EXAM.   INIT.   CA   Saul   Pp.   Frag.   CB   Khay	08/07	/88   F:	rankel	et al.		436	5	548		1	
EXAM. DOCUMEN NUMBER  BA W085/035  BB W088/093  BC 0502812  BD W092/156  BE W093/062  EXAM. INIT.   CA Saul pp. Frag.   Frag.   Frag.   Frag.   CB   Khay		/90 L	adner	et al.		435	)	69.6			
EXAM.   DOCUMENT INIT.   NUMBER     BA   W085/035     BB   W088/093     BC   0502812     BD   W092/156     BE   W093/062     EXAM.   INIT.     CA   Saul     pp.   Frag	02/25	/92 H	uston	et al.		530	)	387	-		
BA W085/035  BB W088/093  BC 0502812  BD W092/156  BE W093/062  EXAM. INIT.   CA Saul Pp. Frag	07/21	/92 H	uston	et al.		530	)	387.	3		
BA   W085/035   BB   W088/093   BC   0502812   BD   W092/156   BE   W093/062   EXAM.   INIT.   CA   Saul   Pp.   Frag.   Frag.   CB   Khay						1		· 		<u> </u>	
BA W085/035  BB W088/093  BC 0502812  BD W092/156  BE W093/062  EXAM. INIT.   CA Saul Pp. Frag		REIGN	PATENT	DOCURED	TS						
BB W088/093  BC 0502812  BD W092/156  BE W093/062  EXAM. INIT.  CA Saul  pp. Frag	DATE	•	UNTRY   DE	CLASS	SUB CLA	•	FIL DAT		ABST ONLY	RACT	ENGLISH LANG Y/N
BC   0502812   BD   W092/156   BE   W093/062   EXAM.   INIT.   CA   Saul   pp.   Frag	3   08/15/8	S5 PCT									
BD W092/156 BE W093/062  EXAM. INIT.  CA Saul pp. Frag	4 01/12/8	88 PCT									
EXAM.   INIT.   CA   Saul   pp.   Frag	1 09/09/9	2 EPO	) ·								
EXAM. INIT.  CA Saul  pp. Frag	32 09/17/	PCT	<u> </u>		 	<u> </u>					
CA Saul	17  04/01/9	 93   PCI	ſ	 	 	1					<u> </u>
CA Saul	OTHER	ART,	JOURNAI	L ARTICL	ES, E	ETC.					
pp. Frag		1	FILING	DATE:				GRO	JP:		
pp. Frag	et al. (1	978) Tì	he Jou	rnal of	Biolo	ogica	ıl Cl	nemis	try.	Vol.	253, No. 2
CB   Khay		Prelim:	inary	Refineme	nt ar	nd St	ruc	tural	Anal	ysis	of the Fab
				· · · · · · · · · · · · · · · · · · ·							""
l liite	et al. (1 rct Imagin hylenetria	g of A	ntibod	ies to C	anin	e Ca	rdia	, pp. c Myo	sin w	297, ith I	"Myocardia Indium-111-
<u> </u>	el (1985)				•		n 2		00_40	ט ייד	Panid and
·	cient site										
CD Che	et al. (1	.985) D	NA, Vo	1. 4, No	o. 2,	pp.	165	-170,			
La La		thods smid D	Superc	oil Sequ	enci	ng:	A Fa	st ar	d Sin	nple 1	Method for

ORH P	m-144	49		ATTY DOCKET NO.: PP0926.105							
nform	MOITA	DISCLOSURE S	TATEMENT	APPLICANT: Huston et al.							
				Serial No.: 09/558,741							
				FILING I	DATE: 4/	GROUP:	UP: unassigned				
			FOREI	CN PATENT							
MAX.		DOCUMENT NUMBER	DATE	COUNTRY CODE	CLASS	SUB CLASS	FILING DATE	ABSTRACT ONLY	LANG Y/N		
	BF	V093/11161	06/10/93	PCT		[ [	1	ļ 	<u> </u>		
	BG	W093/11162	06/10/93	PCT		1			<u> </u>		
	ВН	  W093/15210	  08/05/93	PCT	[ 	<u> </u>		1			
	<u> </u>								1		
	<u> </u>					1					
	.										
	1		 			1					
	1	1			1	1		<u> </u>			
*			İ								
· · · · · · · · · · · · · · · · · · ·	İ		İ			İ					
						İ		i			
	1				<u> </u>						
					†						
· .		·			1						
		<u> </u>									
	-										
	+			<u> </u> 							
	-	1	<u> </u>	1				1.			
	<u> </u>	1		1	1		1	1	1		
	+-	1			<u> </u>		<u> </u>		1		
	+		<u> </u>	<u> </u>	<del> </del>	<u> </u>					
<del></del>	+-		_		<u> </u>			<del>-</del>	<u> </u>		
	<u> </u>		<u> </u>		<u> </u>		<u> </u>		<u> </u>		

ORM PTO	-1449		ATTY DOCKET NO.: PP0926.105				
NYORHAT	ION DIS	CLOSURE STATEMENT	APPLICANT: Huston et al.				
			Serial No.: 09/558,741				
EXAM. INIT.			FILING DATE: 4/26/00 GROUP: unassigned				
	T		GROUT.				
	CE		5) Cancer Research, Vol. 45, pp. 1214-1221,				
		Cancer Immunotoxin	nocolonal Antibodies for the Development of Breast				
	CF	Fisher et al. (198	86) Journal of Clinical Oncology. Vol. 4, No. 6, pp.				
	i	and Royal Project	r Results From the National Surgical Adjuvant Breast (NSABP) Clinical Trial Evaluating the Use of L-Pheny-				
		lalanine Mustard	(L-PAM) in the Management of Primary Breast Cancer"				
	CG	   Satou et al (198	6) J. Hol. Biol., Vol. 190, pp. 593-604, "Phosphocho-				
	i	line Binding Immu	noglubolin Fab McPC603 An X-ray Diffraction Study				
		at 2.7 A"					
	СН	  Amit et al. (1986	) Science, Vol. 233, pp. 747-753, "Three-Dimensional				
		Structure of An A	ntigen-Antibody Complex at 2.8 A Resolution"				
	CI	Sheriff et al. (1	987) Proc. Natl. Acad. Sci. USA, Vol. 84, pp. 8075-				
		8079, "Three-dime	nsional structure of an antibody-antigen complex"				
	CJ	Colman et al. (19	87) Nature, Vol. 326, pp. 358-363, "Three-dimensional				
		structure of a co	mplex of antibody with influenza virus neuraminidase"				
·	CK	Bartlet et al. (1	987) The Lancet, Vol. II, No. 8552, pp. 171-175,				
	.	"Adjuvant Tamoxif The Scottish Tria	en in the Management of Operable Breast Cancer:				
	i	The Scottish IIIa	II				
	CL	Aisner et al., (1	987) Journal of Clinical Oncology, Vol. 5, No. 10, pp				
		Each ± MER) for M	otherapy Versus Chemoimmunotherapy (CAF v CAFVP v CMF Hetastatic Carcinoma of the Breast : A CALGB Study"				
	l cv	Į.					
	CH	"Protein engineer	188) Proc. Natl. Acad. Sci., Vo. 85, pp. 5879-5883, ring of antibody binding sites: Recovery of specific				
	i	activity in an an	nti-digoxin single-chain Fv analogue produced in				
	İ	Eschericha coli"					
	[CN	  Sefton (1988) Tea	ends in Genetics, Vol. 4, No. 9, pp. 247-248, "neus				
	-  <del></del> -	about c-erb-B-2 a	and HER2"				
	l CO	Bird et al (100	38) Science Vol 2/2 pp /22 /2/ #5:1- Ch-:-				
	1	Antigen-Binding B	38) Science, Vol. 242, pp. 423-426, "Single-Chain Proteins"				
	CP	Vogel et al (100	88) Biochemistry, Vol. 28, pp. 2961-2966, "Binding				
	-i	Domains and Epito	opes in Platelet-Derived Growth Factor"				
	l I CQ	  Orlandi et al /1	1989) Proc. Natl. Acad. Sci. USA, Vol. 86, pp. 3833-				
<del></del>	<u> </u>	1 <u>3837, "Cloning in</u>	mmunoglobulin variable domains for expression by the				
	_!	polymerase chain	reaction"				
EXAMINE	r R		DATE CONSIDERED				
			1				

FORM PTO	-1449		ATTY DOCKET NO.: PP0926.105
INFORHAT	ION DISC	CLOSURE STATEMENT	APPLICANT: Huston et al.
			Serial No.: 09/558,741
EXAM. INIT.	T	Т.	FILING DATE: 4/26/00   GROUP: unassigned
	CR	Distribution and	Cancer Research Vol. 49, No. 11, pp. 3070-3080, Physical Properties of BCA200, a H 200,000 Glyco- ly Associated with Human Breast Cancer"
	cs	  Dillman (1989),	Annals of Internal Hedicine, Vol. 111, pp. 592-603, odies for Treating Cancer"
	СТ	Glockshuber et al	. (1990) Biochemistry, Vol. 29, pp. 1362-1367, Strategies to Stabilize Immunoglobulin F. Fragments"
-	СИ	Queen et al. (198	9) Proc. Natl. Acad. Sci., Vol. 86, pp. 10029-10033, body that binds to the interleukin 2 receptor"
	CV	Hird et al. (1990   with Monoclonal A	) Genes and Cancer, pp. 183-189, "Immunotherapy ntibodies"
	CW	No. 25, pp. 15198	0) The Journal of Biological Chemistry, Vol. 265, -15202, "Anti-Tac(Fv)-PE40, a Single Chain Antibody n Protein Directed at Interleukin 2 Receptor
	CX	HcGuire et al. (1	990) Journal of the National Cancer Institute, Vol. 82
	CY	Negative Breast C	
-		Abstract Book Pro	90) The Journal of Nuclear Medicine, Vol. 31, No. 5, ceedings of the 37th Annual Meeting, "Characteriza- and Biodistribution of Tc-99m Labeled Single Chain tent (sFv)"
	CZ	Colcher et al. (1   1197, "In Vivo Tu   Binding Protein"	990) J. Natl. Cancer Inst., Vol. 82, No. 14, pp. 1192- umor Targeting of a Recombinant Single-Chain Antigen-
	CCA	  Batra et al. (199  Vol. 171, No. 1,	00) Biochemical and Biophysical Research Communications pp. 1-6, "TGFa-anti-Tac(Fv)-PE40: A Bifunctional Toxional Solid With EGF or IL2 Receptors"
	ССВ	Fusion Protein Co	Biochemistry, Vol. 29, pp. 8024-8030, "A Bifunctional ontaining Fc-Binding Fragment of B of Staphylococcal
	ccc	Huston et al. (19	Germinal to Antidigoxin Single-Chain Fv"  990) Bispecific Antibodies and Targeted Cellular Cyto- International Conference, pp. 201-206, "Bifunctional Fusion Proteins"
	CCD  -	  Huston et al. (19	990) Academic Press, Inc., Methods in Enzymology, Vol. "Protein Engineering of Single-Chain Fv Analogs and
EXAMINE	R		DATE CONSIDERED

FORM PTO	-1449		ATTY DOCKET NO.: PP0926.105
		LOSURE STATEMENT	APPLICANT: Huston et al.
			-
EXAN.			Serial No.: 09/558,741
INIT.			FILING DATE: 4/26/00 GROUP: unassigned
	CCE	  Whitlow et al. (19	991), Hethods: A Companion to Hethods in
		Enzymology, Vol.	2, No. 2, pp. 97-105, "Single-Chain Fv
		Proteins and Thei	r Fusion Proteins"
	CCF	Nedelman et al. (	1991) Abstract Form for Scientific Papers, No. 32070
		The Society of Nu	clear Medicine 38th Annual Meeting, "Rapid Infarct
	[ ]	Myocardial Infarc	w Tc-99m Antimyosin sFv Fragment: Evaluation in Acute
	İ		
	CCG		gnosis and Therapy"
	1	Microodles III Dia	gnosis and inerapy
	I CCH	Clackson et al. (	1991) Nature, Vol. 352, pp. 624-628, "Making antibody
		iragments using p	hage display libraries"
	CCI		) Holecular Immunology, Vol. 28, No. 8, pp. 915-917,
[ [			200 and c-erbB-2 Indicated by Reactivity of Monoclonal Recombinant c-erbB-2"
	İ	Microodies with F	Recombinant C-erbs-2
	CCJ		1991) Cancer Research, Vol. 51, pp. 6363-6371,
<b> </b> 	 		inding Properties, Metabolism, and Tumopr Targeting of Derived from the Pancarcinoma Monoclonal Antibody
1	ļ	CC49"	berived from the rancaremonia honocional Alerody
1	CCK		1) I Consid Bioches Wales Biol Wal /2 No. 1 2
	- CCK	pp. 1-7. "Diminut	2) J. Steroid Biochem. Molec. Biol., Vol. 43, No. 1-3, tion of Antibodies Directed Against Tumor Cell Surface
ļ	İ	Epitopes: A Sing	le Chain Fv Fusion Molecule Specifically Recognizes the
1		Extracellular Dor	main of the c-erbB-2 Receptor"
i	CCL	Pack et al. (199)	2) Biochemistry, Vol. 31, No. 6, pp. 1579-1584,
		"Miniantibodies:	Use of Amphipathic Helics To Produce Functional,
	1 1	chia coli"	ed Dimeric Fv Fragments with High Avidity in Escheri-
İ			
ļ	CCH	Yokota et al. (1	992) Cancer Research, Vol. 52, pp. 3402-3408, "Rapid n of a Single-Chain Fv and Comparision with Other
		Immunoglobulin F	
	l I CCN	Cumbon on a) (1	002) The Journal of January Wal 1/0 No 1
	- CCN	pp. 120-126, "Co	992) The Journal of Immunology, Vol. 149, No. 1, mparative Stabilities in Vitro and in Vivo of a Recom-
	.		ibody FvCys Fragment and a bisFvCys Conjugate"
	CCO	   Vels et al. (199	2) Biotechnology, Vol. 10, pp.1128-1132, "Construction
	1	Bacterial Expres	sion and Characterization of a Bifunctional Single-
	1		Phosphatase Fusion Protein Targeted to the Human ERBB-2
		Receptor"	
	CCP		992) Cancer Research, Vol. 52, pp. 6413-6417,
	1	["Differential Me	etabolic Patterns of Iodinated versus Radiometal rcinoma Single-Chain Fv Holecules"
1		Cheraten Antical	CTHOMA STURTE-CHAIN IN HOTECUTES
EXAMIN	ER		DATE CONSIDERED

FORH PTO	)-1449		ATTY DOCKET NO.: PP0926.105				
INFORKAT	rion disc	LOSURE STATEMENT	APPLICANT: Huston et al.				
			Serial No.: 09/558,741				
EXAH.							
INIT.	1		FILING DATE: 4/26/00   GROUP: unassigned				
	ccq	Wels et al. (1992)	Cancer_Research, Vol. 52, pp. 6310-6317, "Selective				
			or Cell Growth by a Recombinant Single-Chain Antibody the erbB-2 Receptor"				
	CCR	  Nedelman et al. ()	1993) The Journal of Nuclear Medicine, Vol. 34, pp.				
		234-241, "Rapid II	nfarct Imaging with a Technitium-99m-Labeled Anti-				
		myosin Recombinant Acute Myocoardial	t Single-Chain Fv: Evaluation in a Canine Hodel of Infarction"				
	lccs	  Adams et al. (199)	3) Abstract, International Conference on Monoclonal				
-		Antibody Immunocon	njugates for Cancer, "Demonstratioon of in vivo				
	l I	specificity of 12	5I-741F8 sFv, a single-chain Fv molecule"				
	CCT	Huston et al. (19	93) Immunotechnology, Proceedings of the 21st Federal				
		of European Bioch	emical Societies Keeting, Dublin, pp. 47-60, "Single- ology of Fv analogues and fusion proteins"				
	ccu		(1993) Biotechnology, Advances in Gene Technology				
			ng and Beyond, Proceedings of the 1993 Miami Bio/				
			Symposium, "Refolding of Single-Chain Fv with c- (sFv'): Formation of Disulfide-Bonded Homodimers of				
	İ		Anti-digoxin sFv'"				
	l ccv	Huston et al. (19	93) Intern. Rev. Immunol., Vol. 10, pp. 195-217,				
		"Hedical Applicat	ions of Single-Chain Antibodies"				
	CCW		1993) Abstract, The Tenth International Hammersmith				
	i	Conterence, "Demo	nstration of in vivo tumor specificity of monovalent				
		Fv molecule"	s of 1251-741F8 sFv, an anti-c-erbB-2 single-chain				
	CCX	Huston et al. (Ma	y 1993) Abstract for the 10th Hammersmith Keeting				
<del></del>		"Refolding and Ch	paracterization of single-chain Fv analogues having				
		C-terminal cystei	ne (sFv): physicochemical behavior in vitro and tumor				
		directed to the c	vivo of monovalent sFv and bivalent (sFv) <sub>2</sub> species c-erbB-2 tumor antigen and digoxin"				
	CCY	  Holliger_et_al_/	(1993) Proc. Natl. Acad. Sci. USA, Vol. 90, pp. 6444-				
		6448, "Diabodies:	Small bivalent and bispecific antibody fragments"				
	ccz	Adams et al. (199	93) Cancer Research, Vol. 53, pp. 4026-4034, "Highly				
		Specific in Vivo Anti-c-erbB-2 Sir	Targeting by Monovalent and Divalent Forms of 741F8				
	CCCA	Jacobs (1991) Bi	otechnology 9:258-262.				
	СССВ	Reichmann et al.	(1988) Nature 332: 323-327.				
EXAKINI	<u>+</u> en						
	054/3 AMS		DATE CONSIDERED				

SHEET	7	OF	7
-------	---	----	---

H PT	0-144	9	<u> </u>	ATTY DOCKET NO.: PP0926.105								
ORHA	TION	DISCLOSURE ST	ATEHENT _	APPLICANT	r: Hust	on e	t al.					
			•	Serial No	09/55	8,74	41					
			\ \{_	FILING D	ATE: 4/2	26/00	)		GROUP:	un	assign	ed
			U.S.	PATENT	DOCUHENT	rs	· 		SUB		PTLIN	G DATE
AH. IT.	[ 	DOCUMENT	DATE	NAHE			CLA	ss	CLAS	<u>s</u>		PROPRIATE
	AG	5,258,498	11/02/93	Huston	et al.		530		350		<u> </u>	
	AH	5,260,203	11/09/93	Ladner	et al.		435		172.	3	<u> </u>	
	AI	5,571,894	11/05/96	Wels e	t al.		<u> </u>		<u> </u>		<u> </u>	
	AJ	5,587,458	12/24/96	King e	t al.				1		<del> </del>	
	i -	i					<u> </u>		<u> </u>		<u> </u>	
	1						<u> </u>		<u> </u>		<u> </u>	
	_!		FOREI	GN PATENT	DOCUMEN	NTS_			LING	ARC	TRACT	ENGLISH
KAN.	1	DOCUMENT NUMBER	DATE	COUNTRY CLASS		SU			TE ONL			LANG Y/N
NIT.	+	NORDER	DAID						i 1			
	-	-			<u> </u>				<u> </u>			
	<u> </u>	<u> </u>			<u> </u>	┼-						
			j		<u> </u>	-		 				-
	1				<u> </u>	<u> </u>		<u> </u>		<u> </u>		1
			\ \		1	<u> </u>		<u> </u>		<u>i</u>		1
			OTHER AR	T, JOURNA	AL ARTIC	LES,	ETC.					
EXA					G DATE:				GRO	UP:		
INI	1.	CCCC   Hough	on, Abstrac			, Se	rial	No.	UO1_C	A518	80-05	
	1	CCCC   Houst	on, Austrac			· · ·						
		CCCD Pluck	thun (1992)	"Mono-	and Biva	lent	Anti	bod	y Frag	gment	s Pro	duced in
	-	Escherichia	coli: Engir	neering,	Folding	and	Antig	gen	Bindir	ıg,"	Immun	ological
	<del></del>	Reviews, 130	: 151-188.									
<u> </u>	<del>,</del>	<u> </u>			l n	ATE	CONS	LDER	ED .			
EXA.	HINER						301.0					

# COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231



# FORM PTO-1449 (Modified) LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)

Sheet <u>1</u> of <u>1</u>

In the AMMAN of James S. HUSTON, et al.

47 TATCH

Serial No.: 09/558,741

Art Unit: 1644

70

Filed: April 26, 2000

Examiner: T. Cunningham

Title: BIOSYNTHETIC BINDING PROTEINS FOR IMMUNO-TARGETING

U.S. PATENT DOCUMENTS

Exam. Init.	Ref. Desig.	Document No.	Date	Name	Class	Sub Class	Filing Date
101	AA-1	5,877,305	March 2, 1999	Huston et al.			
¥A	AB-1	6,054,561	April 25, 2000	Ring			

#### FOREIGN PATENT DOCUMENTS

Exam. Init.	Ref. Desig.	Document No.	Publication Date	Country or Patent Office	Class	Sub Class	Trans YES	lation NO
	AC-1							

OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, etc.)

Exam. Init.	Ref. Desig.	Description
	AD-1	

Examiner:

Date Considered:

EXAMINER. Initial if citation considered whether or not the citation conforms with MPEP609. Draw a line through the citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

# Notice of References Cited Application/Control No. 09/558,741 Examiner Larry R. Helms Applicant(s)/Patent Under Reexamination HUSTON ET AL. Page 1 of 1

#### **U.S. PATENT DOCUMENTS**

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Name	Classif	ication
	Α	US-6,207,804	03-2001	Huston et al		
	В	US-				
	С	US-				
	D	US-				
	Ε	US-				
	F	US-				
	G	US-				·=
	Н	US-				
	1	US-				
	J	US-				
	к	US-				
	L	US-				
	М	US-				

#### FOREIGN PATENT DOCUMENTS

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Country	Name	Classification
	N					
	0	•				
	Р					
	Q					
<u></u>	R					
	s					
	Τ	·				

#### NON-PATENT DOCUMENTS

*		Include as applicable: Author, Title Date, Publisher, Edition or Volume, Pertinent Pages)		
	U	Klausner, BioTechnology 4:1041 and 1043, 12/86		
	٧	Rudikoff et al., Proc. Natl. Acad. Sci. USA 79:1979-83, 1982		
	w	Pastan et al., Cell 47:641-648, 12/86		
	х	Jones et al., Nature 321:522-25, 5/86		

\*A copy of this reference is not being furnished with this Office action. (See MPEP § 707.05(a).) Dates in MM-YYYY format are publication dates. Classifications may be US or foreign.